Matthew S. Dietz
No Rating Available
(Learn About Our Rating System)

Matthew S. Dietz, DO, MSEd

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
Get Directions

  • Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.

    In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs.

    Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network.

    Specialties

    Board Certification

    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
    American Board of Pediatrics (Pediatrics)

  • Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.

    In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs.

    Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Associate Professor (Clinical)
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
    American Board of Pediatrics (Pediatrics)

    Education history

    Undergraduate Chemistry - Franklin & Marshall College B.A.
    Professional Medical Osteopathic Medicine - University of New England College of Osteopathic Medicine D.O.
    Graduate Training Medical Education - University of New England College of Osteopathic Medicine M.S.
    Internship/Residency Pediatrics - Oregon Health & Science University Intern/Resident
    Residency Pediatrics - Oregon Health & Science University Chief Resident
    Fellowship Pediatric Hematology/Oncology - Oregon Health & Science University Fellow
    Graduate Training Human Investigations - Oregon Health & Science University Certificate

    Selected Publications

    Journal Article

    1. Lamble AJ, Dietz M, Laderas T, McWeeney S, Lind EF (2018). Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. J Immunol Methods, 453, 44-52. (Read full publication)
    2. Dietz M, Jones M, Svoboda M, Finanger E (2016). Case 3: Episodic Weakness in an 18-month-old Girl. Pediatr Rev, 37(5), 218-9. (Read full publication)
    3. Dietz MS, Beach CZ, Barajas R, Parappilly MS, Sengupta SK, Baird LC, Ciporen JN, Han SJ, Loret de Mola R, Cho YJ, Nazemi KJ, McClelland S 3rd, Wong MH, Jaboin J (2020). Measure Twice: Promise of Liquid Biopsy in Pediatric High-Grade Gliomas. Advances in radiation oncology, 5(2), 152-162. (Read full publication)
    4. McMahon NP, Jones JA, Anderson AN, Dietz MS, Wong MH, Gibbs SL (2023). Flexible Cyclic Immunofluorescence (cyCIF) Using Oligonucleotide Barcoded Antibodies. Cancers, 15(3),
    5. Gupta A, Dietz MS, Riedel RF, Dhir A, Borinstein SC, Isakoff MS, Aye JM, Rainusso N, Armstrong AE, DuBois SG, Wagner LM, Rosenblum JM, Cohen-Gogo S, Albert CM, Zahler S, Chugh R, Trucco (2024). Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board. Cancer, 130(23), 4028-4039. (Read full publication)
    6. Dietz MS, Sutton TL, Walker BS, Gast CE, Zarour L, Sengupta SK, Swain JR, Eng J, Parappilly M, Limbach K, Sattler A, Burlingame E, Chin Y, Gower A, Mira JLM, Sapre A, Chiu YJ, Clayburgh DR, Pommier SJ, Cetnar JP, Fischer JM, Jaboin JJ, Pommier RF, Sheppard BC, Tsikitis VL, Skalet AH, Mayo SC, Lopez CD, Gray JW, Mills GB, Mitri Z, Chang YH, Chin K, Wong M (2021). Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Scientific reports, 11(1), 13630. (Read full publication)
    7. Parekh D, Lin H, Batajoo A, Peckham-Gregory E, Karri V, Stanton W, Scull B, Fleishmann R, El-Mallawany N, Eckstein OS, Prudowsky ZD, Gulati N, Agrusa JE, Ahmed AZ, Chu R, Dietz MS, Goldman SC, Hogarty MD, Imran H, Intzes S, Kim JM, Kopp LM, Levy CF, Neff P, Pillai PM, Sisk BA, Schiff DE, Trobaugh-Lotrario AD, Walkovich K, McClain KL, Allen C (2024). Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. British journal of haematology, 204(5), 1888-1893. (Read full publication)
    8. Dietz MS, Al-Ibraheemi A, Davis JL, Hawkins CM, Craig BT, Dasgupta R, Geller DS, Shulman DS, Cohen-Gogo S, Gupta A, Whiteway SL, Slotkin EK, Heske CM, Ahmed SK, Indelicato DJ, Albert CM, Montgomery N, Sandberg JK, Grier HE, Krailo M, Isakoff MS, Rubin E, Lawlor ER, DuBois SG, Mascarenhas L, Grohar PJ, Binitie O, Reed D, Janeway K, Roberts RD, Bailey K (2024). Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. Journal of the National Comprehensive Cancer Network, 1-7. (Read full publication)

    Review

    1. Vagher J , Dietz MS , Schiffman JD, Kohlmann W, Maese (2022). Germline Predisposition to Soft Tissue Sarcoma. Journal of Cancer Metastasis and Treatment, 8(31),